LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457
Recruiting
This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * BMI of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian. People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps peop... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: The Institute for Liver Health, LLC, Flagstaff, Arizona +436 locations
Conditions: Metabolic Dysfunction Associated Steatohepatitis
Register for Updates
TIDHI Mental Health in IBD Patients Study
NCT07013578
Recruiting
The purpose of this study is to test the impact of Healing Circuits™; a structured mental health support model on IBD patients. The eligible study participants will be randomly divided into two groups: 1. the group receiving structured mental health support with a social worker and 2. the group receiving structured mental health support via a self-directed online curriculum. Both groups will be receiving the same type of therapy, Healing Circuits™, but the group receiving the therapy via the onl... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/05/2025
Locations: Toronto Immune and Digestive Health Institute, North York, Ontario
Conditions: Crohn Disease (CD), Ulcerative Colitis (UC), Inflammatory Bowel Disease (IBD)
Register for Updates
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873
Recruiting
The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This study consists of a screening, a 4-week dapagliflozin run-in period for participants naïve to SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or dapagliflozin; and a 6-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin a... Read More
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
08/05/2025
Locations: Research Site, Fairhope, Alabama +623 locations
Conditions: Chronic Kidney Disease and Hypertension
Register for Updates
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
NCT05707377
Recruiting
The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary membranous nephropathy (PMN) who are on optimal supportive care.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/05/2025
Locations: Amicis Research Center, Northridge, California +68 locations
Conditions: Primary Membranous Nephropathy
Register for Updates
Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients
NCT04289142
Recruiting
Anesthesia is a drug induced, reversible, comatose state that facilitates surgery and it is widely assumed that cognition returns to baseline after anesthetics have been eliminated. However, many patients have persistent memory impairment for weeks to months after surgery. Cardiac surgery appears to carry the highest risk of postoperative cognitive dysfunction (POCD). These cognitive deficits are associated with increased mortality, prolonged hospital stay and loss of independence. The investiga... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
08/05/2025
Locations: Royal Columbian Hospital, Vancouver, British Columbia +5 locations
Conditions: Delirium, Cognitive Dysfunction, Cognition Disorder, Neurocognitive Disorders, Mental Disorders, Confusion, Neurobehavioral Manifestations, Neurologic Manifestations, Nervous System Diseases, Signs and Symptoms, Dexmedetomidine, Hypnotics and Sedatives, Central Nervous System Depressants, Physiological Effects of Drugs, Analgesics, Non-Narcotic, Analgesics, Molecular Mechanisms of Pharmacological Action
Register for Updates
Short Duration Electrical Stimulation to Improve Outcomes After Cubital Tunnel Release (SELECT) Trial
NCT05980767
Recruiting
A novel temporary peripheral nerve stimulation system that delivers electrical stimulation therapy in a cubital tunnel release model will be evaluated for feasibility.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/05/2025
Locations: Hamilton General Hospital, Hamilton, Ontario +1 locations
Conditions: Neuropathy;Peripheral
Register for Updates
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06290934
Recruiting
The goal of this study is to learn if GS-1427 is effective in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with GS-1427 with participants treated with placebo. The primary objective of this study is to assess the efficacy of GS-1427, compared with placebo control, in achieving clinical response at Week 12.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/05/2025
Locations: Onyx Clinical Research (Clinic Location), Peoria, Arizona +184 locations
Conditions: Ulcerative Colitis
Register for Updates
IA Carboplatin + Radiotherapy in Relapsing GBM
NCT03672721
Recruiting
Treatment of glioblastoma involves an optimal surgery, followed by a combination of radiation and temozolomide chemotherapy. Progression-free survival (PFS) with this treatment is only 6.9 months and relapse is the norm. The rationale behind the fact that limited chemotherapy agents are available in the treatment of malignant gliomas is related to the blood-brain barrier (BBB), which limits drug entry to the brain. Intraarterial (IA) chemotherapy allows to circumvent this. Using IA delivery of c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: CHUS, Sherbrooke, Quebec
Conditions: Glioblastoma Multiforme, Relapse
Register for Updates
A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors
NCT05538130
Recruiting
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) administered as a single agent and in combination with other study medications in people with solid tumors. This study is seeking participants who have an advanced solid tumor for which the available treatments are no longer effective in controlling their cancer. All participants in this study will receive PF-07799544. PF-07799544 comes as a tablet to take by mouth daily (initially 2 times p... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
08/05/2025
Locations: Highlands Oncology Group, Fayetteville, Arkansas +47 locations
Conditions: Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Colorectal Cancer
Register for Updates
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145
Recruiting
This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥18 years) with RMS, PPMS, or NRSPMS who were previously enrolled in the Phase 2b LTS (LTS16004) or 1 of the 4 Phase 3 tolebrutinib pivotal trials (GEMINI 1 \[EFC16033\], GEMINI 2 \[EFC16034\], HERCULES \[EFC16645\], or PERSEUS \[EFC16035\]). SUBSTUDY: ToleDYNAMIC substudy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: University of Alabama at Birmingham- Site Number : 8400013, Birmingham, Alabama +322 locations
Conditions: Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Register for Updates
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
NCT05371613
Recruiting
This is a Phase 2/3, multiregional, two-arm, double-blind, randomized, active (standard-of-care)-controlled study of the efficacy and safety of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme-replacement therapy (ERT) for mucopolysaccharidosis type II (MPS II). Participants may also qualify to enter an open-label treatment phase with DNL310 or idursulfase based on pre-specified criteria.
Gender:
ALL
Ages:
Between 2 years and 25 years
Trial Updated:
08/04/2025
Locations: UCSF Benioff Children's Hospital Oakland, Oakland, California +31 locations
Conditions: Mucopolysaccharidosis II
Register for Updates
Improving Efficacity of Sleeve Gastrectomy With Naltrexone/Bupropion Extended-release Tablet
NCT06620562
Recruiting
The goal of this clinical trial is to assess the impact of combination therapy with Naltrexone-Bupropion (NB) in the post-operative period of sleeve gastrectomy (SG). on a) weight loss, b) resolution of comorbidities and c) eating behaviors. Researchers will compare SG-NB group with SG-placebo group to see if they experience significantly higher excess weight loss (EWL) at 12 and 24 months and if there is a significantly higher percentage of patients with an EWL above 50% in the SG-NB group ver... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/04/2025
Locations: Criucpq-Ul, Quebec City, Quebec
Conditions: Obesity; Drug, Obesity, Morbid
Register for Updates